Characterization and molecular cloning of vascular neuropeptide Y receptor subtypes in pig and dog

Regulatory Peptides

Volumn 75-76, Issue , 1998, Pages 55-70

  Malmström, Rickard E ^a   Hökfelt, Tomas ^a   Björkman, Jan Arne ^b   Nihlén, Carina ^a   Byström, Mona ^c   Ekstrand, A Jonas ^c   Lundberg, Jan M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c Dept of Behavioural Medicine   (Sweden)

Author keywords

BIBP 3226; Kidney; Spleen; SR 120107A; Vasoconstriction

Indexed keywords

MESSENGER RNA; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y DERIVATIVE; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; RECEPTOR SUBTYPE; SR 120107A; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DNA LIBRARY; DOG; GENE EXPRESSION; GUINEA PIG; HISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; MEMBRANE BINDING; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SPLEEN; VASOCONSTRICTION;

AMINO ACID SEQUENCE; ANIMALS; ARGININE; BASE SEQUENCE; CLONING, MOLECULAR; DNA PRIMERS; DNA, COMPLEMENTARY; DOGS; HUMANS; IN SITU HYBRIDIZATION; KIDNEY; MOLECULAR SEQUENCE DATA; PEPTIDE YY; RECEPTORS, NEUROPEPTIDE Y; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE HOMOLOGY, AMINO ACID; SPECIES SPECIFICITY; SPLEEN; SWINE; VASOCONSTRICTION;

CANIS FAMILIARIS; MAMMALIA; SUIDAE; SUS SCROFA;

EID: 0032566815     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(98)00053-6     Document Type: Article

References (35)

1. Tatemoto K., Carlquist M., Mutt V. Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature. 296:1982;659-660.
2. Wahlestedt C., Reis D.J. Neuropeptide Y-related peptides and their receptors - are the receptors potential therapeutic drug targets? Annu Rev Pharmacol Toxicol. 32:1993;309-352.
3. Lundberg J.M., Terenius L., Hökfelt T., Martling C.-R., Tatemoto K., Mutt V., Polak J., Bloom S., Goldstein M. Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol Scand. 116:1982;477-480.
4. Herzog H., Hort Y.J., Ball H.J., Hayes G., Shine J., Selbie L.A. Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc Natl Acad Sci USA. 89:1992;5794-5798.
5. Larhammar D., Blomqvist G.A., Yee F., Jazin E., Yoo H., Wahlestedt C. Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Y1 type. J Biol Chem. 267:1992;10935-10938.
6. Rose P.M., Fernandes P., Lynch J.S., Frazier S.T., Fisher S.M., Kodukula K., Kienzle B., Seethala R. Cloning and functional expression of a cDNA encoding a human type 2 neuropeptide Y receptor. J Biol Chem. 270:1995;22661-22664.
7. Larhammar D. Extraordinary structural diversity of NPY-family receptors. In: Grundemar L, Bloom SR, editors. Neuropeptide Y and Drug Development. London: Academic Press, 1997:87-105.
8. Lundberg J.M., Hemsén A., Larsson O., Rudehill A., Saria A., Fredholm B.B. Neuropeptide Y receptor in pig spleen: binding characteristics, reduction of cyclic AMP formation and calcium antagonist inhibition of vasoconstriction. Eur J Pharmacol. 145:1988;21-29.
9. Doods H.N., Krause J. Different neuropeptide Y receptor subtypes in rat and rabbit vas deferens. Eur J Pharmacol. 204:1991;101-103.
10. Serradeil-Le Gal C., Valette G., Rouby P.E., Pellet A., Villanova G., Foulon L., Lespy L., Neliat G., Chambon J.P., Maffrand J.P., Le Fur G. SR 120107A and SR 120819A: two potent and selective orally-effective antagonists for NPY Y1 receptors. Soc Neurosci Abstr. 20:1994;907.
11. 1 receptor antagonist: BIBP3226. Eur J Pharmacol. 271:1994;R11-R13.
12. 1 receptor accounts for the long lasting part of the sympathetic contraction in guinea-pig vena cava: evidence using SR 120107A. Acta Physiol Scand. 155:1995;329-330.
13. Malmström R.E., Lundberg J.M. Neuropeptide Y accounts for sympathetic vasoconstriction in guinea-pig vena cava: evidence using BIBP 3226 and 3435. Eur J Pharmacol. 294:1995;661-668.
14. Lundberg J.M., Modin A. Inhibition of sympathetic vasoconstriction in pigs in vivo by the neuropeptide Y-Y1 receptor antagonist BIBP 3226. Br J Pharmacol. 116:1995;2971-2982.
15. 1 receptor mediated sympathetic vasoconstriction in pigs in vivo. Eur J Pharmacol. 305:1996;145-154.
16. 2 radioligands. J Pharmacol Exp Ther. 272:1995;673-680.
17. 3H]BIBP3226. Eur J Pharmacol. 278:1995;239-242.
18. Eva C., Keinänen K., Monyer H., Seeburg P., Sprengel R. Molecular cloning of a novel G protein-coupled receptor that may belong to the neuropeptide receptor family. FEBS Lett. 271:1990;81-84.
19. Gerald C, Walker MW, Branchek TA, Weinshank RL. Nucleic acid encoding neuropeptide Y/peptide YY (Y2) receptors and uses thereof. Int Patent Application 1995;WO 95/21245.
20. Dagerlind Å., Friberg K., Bean A.J., Hökfelt T. Sensitive mRNA detection using unfixed tissue: combined radioactive and non-radioactive in situ hybridization histochemistry. Histochemistry. 98:1992;39-49.
21. Larhammar D, Söderberg C, Blomqvist AG. Evolution of the neuropeptide Y family of peptides. In: Colmers WF, Wahlestedt C, editors. The Biology of Neuropeptide Y and Related Peptides. Totowa: Humana Press, 1993:1-41.
22. Stark R.D. Conductance or resistance. Nature. 217:1968;779.
23. Rudolf K, Eberlein W, Engel W, Mihm G, Doods H, Wieland H-A, Willim K-D, Krause J, Dollinger H, Esser F, Schnorrenberg G, Entzeroth M, Wienen W. Amino acid derivates, medicaments containing these compounds and process for preparing the same. Int Patent Application 1993;WO 94/17035-A1.
24. Christophe B, Foulon L, Pellet A, Serradeil-Le Gal C, Valette G. Compounds bearing sulphamoyl and amidino radicals, their preparation process and pharmaceutical compositions containing them. Natl Patent Application 1993;FR 9301686.
25. Wharton J., Gordon L., Byrne J., Herzog H., Selbie L.A., Moore K., Sullivan M.H.F., Elder M.G., Moscoso G., Taylor K.M., Shine J., Polak J.M. Expression of the human neuropeptide tyrosine Y1 receptor. Proc Natl Acad Sci USA. 90:1993;687-691.
26. 31] Neuropeptide Y(24-36), with functional specificity for the presynaptic (Y2) receptor. Eur J Pharmacol. 267:1994;253-262.
27. 34]peptide YY, is also a high affinity radioligand for human pancreatic polypeptide 1 receptors. Eur J Pharmacol. 318:1996;485-490.
28. 3H]BIBP3226. NeuroReport. 7:1996;901-904.
29. Bard J.A., Walker M.W., Branchek T.A., Weinshank R.L. Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y and peptide YY. J Biol Chem. 270:1995;26762-26765.
30. Lundell I., Blomqvist A.G., Berglund M.M., Schober D.A., Johnson D., Statnick M.A., Gadski R.A., Gehlert D.R., Larhammar D. Cloning of a human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY. J Biol Chem. 270:1995;29123-29128.
31. Lundberg J.M., Hemsén A., Rudehill A., Härfstrand A., Larsson O., Sollevi A., Saria A., Hökfelt T., Fuxe K., Fredholm B.B. Neuropeptide Y- and alpha-adrenergic receptors in pig spleen: localization, binding characteristics, cyclic AMP effects and functional responses in control and denervated animals. Neuroscience. 24:1988;659-672.
32. Walsh D.A., Wharton J., Blake D.R., Polak J.M. Localization and characterization of neuropeptide Y binding sites in porcine and human colon. Br J Pharmacol. 108:1993;304-311.
33. Price J.S., Kenny A.J., Huskisson N.S., Brown M.J. Neuropeptide Y (NPY) metabolism by endopeptidase-2 hinders characterization of NPY receptors in rat kidney. Br J Pharmacol. 104:1991;321-326.
34. Leys K., Schachter M., Sever P. Autoradiographic localization of NPY receptors in rabbit kidney: comparison with rat, guinea-pig and human. Eur J Pharmacol. 134:1987;233-237.
35. Cheng H.F., Becker B.N., Burns K.D., Harris R.C. Angiotensin II upregulates type-1 angiotensin II receptors in renal proximal tubule. J Clin Invest. 95:1995;2012-2019.